Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...